Swiss drugmaker Novartis has received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the company said on Wednesday. Men with a deadly form of prostate cancer that has spread and who were not helped by other treatments on average survived four months longer after getting Novartis’ […] Read more